Takeda Collaborates with Cerevance to Develop New Therapies for Gastrointestinal Disorders

 Takeda Collaborates with Cerevance to Develop New Therapies for Gastrointestinal Disorders

Takeda Collaborates with Cerevance to Develop New Therapies for Gastrointestinal Disorders

Shots:

  • Cerevance to receive upfront technology access fee, pre/-clinical, development, commercialization milestones of up to $170M/ target and royalties on global sales of products. Takeda will support the research to identify novel target proteins expressed in the CNS and to develop new therapies targeting GI disorders
  • The multi-year collaboration will leverage Cerevance’s NETSseq technology to identify new therapies targeting the unmet medical needs of patients with GI disease
  • Cerevance’s NETSseq target discovery platform utilizes Ab nuclear proteins, ER proteins and membrane proteins along with RNA probes against any cell-type-specific transcripts and enables the measurement of genes

Click here to­ read full press release/ article | Ref: Cerevance | Image: Cerevance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post